TFF Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 0/6
TFF Pharmaceuticals has been growing earnings at an average annual rate of 0.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 74.3% per year.
Belangrijke informatie
0.2%
Groei van de winst
37.1%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 74.3% |
| Rendement op eigen vermogen | -329.8% |
| Nettomarge | -1,612.0% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?
Apr 10
Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?
Sep 27TFF Pharma: The Potential Is Still Very Much Present
Aug 29TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways
Aug 09TFF Pharmaceuticals expands R&D operations with new Austin facility
Jul 14TFF Pharmaceuticals: A Highly Attractive Basket Of Options
May 23We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully
May 17Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation
Jan 06TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly
Dec 02Opbrengsten en kosten
Hoe TFF Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -19 | 9 | 0 |
| 31 Mar 24 | 1 | -20 | 10 | 0 |
| 31 Dec 23 | 1 | -21 | 11 | 0 |
| 30 Sep 23 | 1 | -24 | 12 | 0 |
| 30 Jun 23 | 1 | -27 | 13 | 0 |
| 31 Mar 23 | 0 | -30 | 14 | 0 |
| 31 Dec 22 | 0 | -32 | 14 | 0 |
| 30 Sep 22 | 0 | -34 | 13 | 0 |
| 30 Jun 22 | 0 | -36 | 13 | 0 |
| 31 Mar 22 | 0 | -32 | 11 | 0 |
| 31 Dec 21 | 0 | -31 | 11 | 0 |
| 30 Sep 21 | 0 | -27 | 10 | 0 |
| 30 Jun 21 | 0 | -23 | 10 | 0 |
| 31 Mar 21 | 0 | -22 | 9 | 0 |
| 31 Dec 20 | 0 | -19 | 8 | 0 |
| 30 Sep 20 | 0 | -41 | 7 | 3 |
| 30 Jun 20 | 0 | -39 | 5 | 6 |
| 31 Mar 20 | 0 | -38 | 4 | 7 |
| 31 Dec 19 | 0 | -37 | 3 | 9 |
| 30 Sep 19 | 0 | -9 | 3 | 6 |
| 30 Jun 19 | 0 | -7 | 3 | 3 |
| 31 Mar 19 | 0 | -7 | 3 | 3 |
| 31 Dec 18 | 0 | -5 | 3 | 1 |
| 30 Sep 18 | 0 | -4 | 2 | 1 |
| 30 Jun 18 | 0 | -3 | 2 | 1 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: TFFP is currently unprofitable.
Groeiende winstmarge: TFFP is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TFFP is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.
Versnelling van de groei: Unable to compare TFFP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: TFFP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: TFFP has a negative Return on Equity (-329.84%), as it is currently unprofitable.